請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66043
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蘇銘嘉(Ming-Jai Su) | |
dc.contributor.author | Chi-Tun Ruan | en |
dc.contributor.author | 阮琪惇 | zh_TW |
dc.date.accessioned | 2021-06-17T00:19:58Z | - |
dc.date.available | 2017-09-18 | |
dc.date.copyright | 2012-09-18 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-06-25 | |
dc.identifier.citation | 1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-1431.
2. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 2000; 247:301-310. 3. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261:32-43. 4. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004; 447:510-518. 5. Illsley NP. Glucose transporters in the human placenta. Placenta 2000; 21:14-22. 6. Skelly PJ, Tielens AG, Shoemaker CB. Glucose Transport and Metabolism in Mammalian-stage Schistosomes. Parasitol Today 1998; 14:402-406. 7. Minkowski O, Bretzel RG. Further reports on diabetes mellitus after the exstirpation of the pancreas. J Mol Med (Berl) 2002; 80:3; discussion 3-4. 8. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 1980; 51:520-528. 9. Polonsky KS, Pugh W, Jaspan JB, Cohen DM, Karrison T, Tager HS, et al. C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. J Clin Invest 1984; 74:1821-1829. 10. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-110. 11. Lopez-Candales A. Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. J Med 2001; 32:283-300. 12. Warren S, Root HF. The Pathology of Diabetes, with Special Reference to Pancreatic Regeneration. Am J Pathol 1925; 1:415-430 411. 13. Junker K, Egeberg J, Kromann H, Nerup J. An autopsy study of the islets of Langerhans in acute-onset juvenile diabetes mellitus. Acta Pathol Microbiol Scand A 1977; 85:699-706. 14. Lohr M, Kloppel G. Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 1987; 30:757-762. 15. Pipeleers D, Ling Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 1992; 8:209-227. 16. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14:619-633. 17. Madsbad S, Krarup T, Reguer L, Faber OK, Binder C. Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics. Diabetologia 1981; 20:530-534. 18. Madsbad S. Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes. Diabetologia 1983; 24:141-147. 19. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005; 48:2221-2228. 20. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007; 61:737-747. 21. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607. 22. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444:840-846. 23. Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep 2003; 5:364-371. 24. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88:2399-2403. 25. Bays HE, Bazata DD, Fox KM, Grandy S, Gavin JR, 3rd. Perceived body image in men and women with type 2 diabetes mellitus: correlation of body mass index with the figure rating scale. Nutr J 2009; 8:57. 26. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52:595-600. 27. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-1053. 28. Weidmann P, Boehlen LM, de Courten M. Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J 1993; 125:1498-1513. 29. Goldstein DA, Massry SG. Diabetic nephropathy: clinical course and effect of hemodialysis. Nephron 1978; 20:286-296. 30. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007; 28:463-491. 31. Taniguchi CM, Ueki K, Kahn R. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 2005; 115:718-727. 32. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106:171-176. 33. Goda T, Yamada K, Sugiyama M, Moriuchi S, Hosoya N. Effect of sucrose and Acarbose feeding on the development of streptozotocin-induced diabetes in the rat. J Nutr Sci Vitaminol (Tokyo) 1982; 28:41-56. 34. Yoshinaga T. [A morphological study on the mechanism of insulin-release, using sulfonylurea, l-leucine, and alpha-ketocarboxylic acids]. Nihon Naibunpi Gakkai Zasshi 1968; 44:741-749. 35. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51:2074-2081. 36. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49:2063-2069. 37. Toyota T, Ueno Y. [Clinical effect and side effect of troglitazone]. Nihon Rinsho 2000; 58:376-382. 38. Filz HP. [Insulin sensitizer. A new therapy option for type 2 diabetic patients]. MMW Fortschr Med 2000; 142:31-33. 39. Iwase M, Yamaguchi M, Yoshinari M, Okamura C, Hirahashi T, Tsuji H, et al. A Japanese case of liver dysfunction after 19 months of troglitazone treatment. Diabetes Care 1999; 22:1382-1384. 40. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20:876-913. 41. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007; 30:1335-1343. 42. Palalau AI, Tahrani AA, Piya MK, Barnett AH. DPP-4 inhibitors in clinical practice. Postgrad Med 2009; 121:70-100. 43. Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81:761-767. 44. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48:2270-2276. 45. Meier JJ, Gallwitz B, Nauck MA. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs 2003; 17:93-102. 46. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93:397-404. 47. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320:323-330. 48. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32:1656-1662. 49. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32:650-657. 50. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009; 11:79-88. 51. Cheng JT, Liu IM, Chi TC, Su HC, Chang CG. Stimulation of insulin release in rats by Die-Huang-Wan, a herbal mixture used in Chinese traditional medicine. J Pharm Pharmacol 2001; 53:273-276. 52. Xiang ZX, Huang C, Peng XJ, Qin Y. [Progress in treatment of diabetes mellitus and complications by Chinese herbal drugs]. Zhong Xi Yi Jie He Xue Bao 2006; 4:321-325. 53. Kedar P, Chakrabarti CH. Effects of bittergourd (Momordica charantia) seed & glibenclamide in streptozotocin induced diabetes mellitus. Indian J Exp Biol 1982; 20:232-235. 54. Blum A, Loerz C, Martin HJ, Staab-Weijnitz CA, Maser E. Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11beta-hydroxysteroid dehydrogenase type 1 inhibitor. J Steroid Biochem Mol Biol 2012; 128:51-55. 55. Tripathi UN, Chandra D. The plant extracts of Momordica charantia and Trigonella foenum-graecum have anti-oxidant and anti-hyperglycemic properties for cardiac tissue during diabetes mellitus. Oxid Med Cell Longev 2009; 2:290-296. 56. Liu JJ, Huang TS, Hsu ML, Chen CC, Lin WS, Lu FJ, et al. Antitumor effects of the partially purified polysaccharides from Antrodia camphorata and the mechanism of its action. Toxicol Appl Pharmacol 2004; 201:186-193. 57. Seto SW, Lam TY, Tam HL, Au AL, Chan SW, Wu JH, et al. Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine 2009; 16:426-436. 58. Hikino H, Mizuno T. Hypoglycemic actions of some heteroglycans of Ganoderma lucidum fruit bodies. Planta Med 1989; 55:385. 59. Zhang HN, He JH, Yuan L, Lin ZB. In vitro and in vivo protective effect of Ganoderma lucidum polysaccharides on alloxan-induced pancreatic islets damage. Life Sci 2003; 73:2307-2319. 60. Higashino H, Suzuki A, Tanaka Y, Pootakham K. [Inhibitory effects of Siamese Tinospora crispa extracts on the carrageenin-induced foot pad edema in rats (the 1st report)]. Nihon Yakurigaku Zasshi 1992; 100:339-344. 61. Cavin A, Hostettmann K, Dyatmyko W, Potterat O. Antioxidant and lipophilic constituents of Tinospora crispa. Planta Med 1998; 64:393-396. 62. Denis G, Gerard Y, Sahpaz S, Laporte R, Viget N, Ajana F, et al. [Malarial prophylaxis with medicinal plants: toxic hepatitis due to Tinospora crispa]. Therapie 2007; 62:271-272. 63. Kadir FA, Othman F, Abdulla MA, Hussan F, Hassandarvish P. Effect of Tinospora crispa on thioacetamide-induced liver cirrhosis in rats. Indian J Pharmacol 2011; 43:64-68. 64. Rungruang T, Boonmars T. In vivo antiparasitic activity of the Thai traditional medicine plant--Tinospora crispa--against Plasmodium yoelii. Southeast Asian J Trop Med Public Health 2009; 40:898-900. 65. Praman S, Mulvany MJ, Allenbach Y, Marston A, Hostettmann K, Sirirugsa P, et al. Effects of an n-butanol extract from the stem of Tinospora crispa on blood pressure and heart rate in anesthetized rats. J Ethnopharmacol 2011; 133:675-686. 66. Praman S, Mulvany MJ, Williams DE, Andersen RJ, Jansakul C. Hypotensive and cardio-chronotropic constituents of Tinospora crispa and mechanisms of action on the cardiovascular system in anesthetized rats. J Ethnopharmacol 2012; 140:166-178. 67. Kongkathip N, Dhumma-upakorn P, Kongkathip B, Chawananoraset K, Sangchomkaeo P, Hatthakitpanichakul S. Study on cardiac contractility of cycloeucalenol and cycloeucalenone isolated from Tinospora crispa. J Ethnopharmacol 2002; 83:95-99. 68. Zaridah MZ, Idid SZ, Omar AW, Khozirah S. In vitro antifilarial effects of three plant species against adult worms of subperiodic Brugia malayi. J Ethnopharmacol 2001; 78:79-84. 69. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26:325-330. 70. Noor H, Ashcroft SJ. Antidiabetic effects of Tinospora crispa in rats. J Ethnopharmacol 1989; 27:149-161. 71. Noor H, Ashcroft SJ. Pharmacological characterisation of the antihyperglycaemic properties of Tinospora crispa extract. J Ethnopharmacol 1998; 62:7-13. 72. Noor H, Hammonds P, Sutton R, Ashcroft SJ. The hypoglycaemic and insulinotropic activity of Tinospora crispa: studies with human and rat islets and HIT-T15 B cells. Diabetologia 1989; 32:354-359. 73. Yonemitsu M, Fukuda N, Kimura T. Studies on the constituents of Tinospora sinensis; I. Separation and structure of the new phenolic glycoside tinosinen. Planta Med 1993; 59:552-553. 74. Choudhary MI, Ismail M, Shaari K, Abbaskhan A, Sattar SA, Lajis NH, et al. cis-Clerodane-type furanoditerpenoids from Tinospora crispa. J Nat Prod 2010; 73:541-547. 75. Lam SH, Ruan CT, Hsieh PH, Su MJ, Lee SS. Hypoglycemic diterpenoids from Tinospora crispa. J Nat Prod 2012; 75:153-159. 76. Sultan KR, Henkel B, Terlou M, Haagsman HP. Quantification of hormone-induced atrophy of large myotubes from C2C12 and L6 cells: atrophy-inducible and atrophy-resistant C2C12 myotubes. Am J Physiol Cell Physiol 2006; 290:C650-659. 77. Tzeng TF, Liu IM, Cheng JT. Activation of opioid mu-receptors by loperamide to improve interleukin-6-induced inhibition of insulin signals in myoblast C2C12 cells. Diabetologia 2005; 48:1386-1392. 78. Liu IM, Chi TC, Shiao GC, Lin MT, Cheng JT. Loss of plasma glucose lowering response to cold stress in opioid mu-receptor knock-out diabetic mice. Neurosci Lett 2001; 307:81-84. 79. Huang BW, Chiang MT, Yao HT, Chiang W. The effect of high-fat and high-fructose diets on glucose tolerance and plasma lipid and leptin levels in rats. Diabetes Obes Metab 2004; 6:120-126. 80. Weng YC, Chiu HL, Lin YC, Chi TC, Kuo YH, Su MJ. Antihyperglycemic effect of a caffeamide derivative, KS370G, in normal and diabetic mice. J Agric Food Chem 2010; 58:10033-10038. 81. Jong-Yuh C, Mei-Fen S. Potential hypoglycemic effects of Chlorella in streptozotocin-induced diabetic mice. Life Sci 2005; 77:980-990. 82. Park SH, Ko SK, Chung SH. Euonymus alatus prevents the hyperglycemia and hyperlipidemia induced by high-fat diet in ICR mice. J Ethnopharmacol 2005; 102:326-335. 83. Zhang Y, Jayaprakasam B, Seeram NP, Olson LK, DeWitt D, Nair MG. Insulin secretion and cyclooxygenase enzyme inhibition by cabernet sauvignon grape skin compounds. J Agric Food Chem 2004; 52:228-233. 84. Schreyer SA, Wilson DL, LeBoeuf RC. C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis 1998; 136:17-24. 85. Tan Y, Kamal MA, Wang ZZ, Xiao W, Seale JP, Qu X. Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome. Clin Sci (Lond) 2011; 120:297-305. 86. Kuftinec DM, Mayer J. Extreme Sensitivity of Obese Hyperglycemic Mice to Caffeine and Coffee. Metabolism 1964; 13:1369-1375. 87. Deng YX, Chen YS, Zhang WR, Chen B, Qiu XM, He LH, et al. Polysaccharide from Gynura divaricata modulates the activities of intestinal disaccharidases in streptozotocin-induced diabetic rats. Br J Nutr 2011; 106:1323-1329. 88. Chi TC, Lee SS, Su MJ. Antihyperglycemic effect of aporphines and their derivatives in normal and diabetic rats. Planta Med 2006; 72:1175-1180. 89. Chi TC, Chen WP, Chi TL, Kuo TF, Lee SS, Cheng JT, et al. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci 2007; 80:1713-1720. 90. Chen WP, Tzeng HJ, Ku HC, Ho YJ, Lee SS, Su MJ. Thaliporphine ameliorates cardiac depression in endotoxemic rats through attenuating TLR4 signaling in the downstream of TAK-1 phosphorylation and NF-kappaB signaling. Naunyn Schmiedebergs Arch Pharmacol 2010; 382:441-453. 91. Chen WP, Chi TC, Chuang LM, Su MJ. Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells. Eur J Pharmacol 2007; 568:269-277. 92. Savage DB, Zhai L, Ravikumar B, Choi CS, Snaar JE, McGuire AC, et al. A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice. PLoS Med 2008; 5:e27. 93. Jaiswal D, Kumar Rai P, Kumar A, Mehta S, Watal G. Effect of Moringa oleifera Lam. leaves aqueous extract therapy on hyperglycemic rats. J Ethnopharmacol 2009; 123:392-396. 94. Vollenweider P. Insulin resistant states and insulin signaling. Clin Chem Lab Med 2003; 41:1107-1119. 95. Bessesen DH. The role of carbohydrates in insulin resistance. J Nutr 2001; 131:2782S-2786S. 96. Lavoie L, Band CJ, Kong M, Bergeron JJ, Posner BI. Regulation of glycogen synthase in rat hepatocytes. Evidence for multiple signaling pathways. J Biol Chem 1999; 274:28279-28285. 97. Jackson C. Diabetes: kicking off the insulin cascade. Nature 2006; 444:833-834. 98. Ginsberg HN. Investigation of insulin resistance during diabetic ketoacidosis: role of counterregulatory substances and effect of insulin therapy. Metabolism 1977; 26:1135-1146. 99. Hollenbeck C, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 1987; 64:1169-1173. 100. Gould GW, Bell GI. Facilitative glucose transporters: an expanding family. Trends Biochem Sci 1990; 15:18-23. 101. Patel N, Huang C, Klip A. Cellular location of insulin-triggered signals and implications for glucose uptake. Pflugers Arch 2006; 451:499-510. 102. Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 1992; 54:885-909. 103. Tie L, Yang HQ, An Y, Liu SQ, Han J, Xu Y, et al. Ganoderma lucidum polysaccharide accelerates refractory wound healing by inhibition of mitochondrial oxidative stress in type 1 diabetes. Cell Physiol Biochem 2012; 29:583-594. 104. Ma XR, Zhou CF, Wang SQ, Wang WQ, Liu YX, Wang SX, et al. [Effects of ganoderma lucidum spores on mitochondrial calcium ion and cytochrome C in epididymal cells of type 2 diabetes rats]. Zhonghua Nan Ke Xue 2007; 13:400-402. 105. Kiho T, Sobue S, Ukai S. Structural features and hypoglycemic activities of two polysaccharides from a hot-water extract of Agrocybe cylindracea. Carbohydr Res 1994; 251:81-87. 106. Cho EJ, Hwang HJ, Kim SW, Oh JY, Baek YM, Choi JW, et al. Hypoglycemic effects of exopolysaccharides produced by mycelial cultures of two different mushrooms Tremella fuciformis and Phellinus baumii in ob/ob mice. Appl Microbiol Biotechnol 2007; 75:1257-1265. 107. Kiho T, Tsujimura Y, Sakushima M, Usui S, Ukai S. [Polysaccharides in fungi. XXXIII. Hypoglycemic activity of an acidic polysaccharide (AC) from Tremella fuciformis]. Yakugaku Zasshi 1994; 114:308-315. 108. Zhang G, Huang Y, Bian Y, Wong JH, Ng TB, Wang H. Hypoglycemic activity of the fungi Cordyceps militaris, Cordyceps sinensis, Tricholoma mongolicum, and Omphalia lapidescens in streptozotocin-induced diabetic rats. Appl Microbiol Biotechnol 2006; 72:1152-1156. 109. Kiho T, Ookubo K, Usui S, Ukai S, Hirano K. Structural features and hypoglycemic activity of a polysaccharide (CS-F10) from the cultured mycelium of Cordyceps sinensis. Biol Pharm Bull 1999; 22:966-970. 110. Wakabayashi S. [The effects of indigestible dextrin on sugar tolerance: III. Improvement in sugar tolerance by indigestible dextrin on the impaired glucose tolerance model]. Nihon Naibunpi Gakkai Zasshi 1993; 69:594-608. 111. Wakabayashi S, Kishimoto Y, Matsuoka A. Effects of indigestible dextrin on glucose tolerance in rats. J Endocrinol 1995; 144:533-538. 112. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-342. 113. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66043 | - |
dc.description.abstract | 名列十大死因的新陳代謝性疾病──糖尿病,常會導致神經與血管併發症,嚴重的話還可能導致截肢。由於人口增長、邁向老年化社會、城市化、不健康的飲食習慣、肥胖人數增加與久坐的生活習慣,讓糖尿病的人口數預計在2000年到2030年間呈倍數增加。根據先前文獻研究指出,糖尿病與胰島素的異常釋放及胰島素敏感度降低有關,從而提高肝臟葡萄糖產生並減少肌肉對於葡萄糖的攝取。如今,已有多種口服降血糖藥物問世,提供糖尿病的相關治療,如:磺胺尿素類、雙胍類、meglitinide衍生物、thiazolidinediones (TZD) 類衍生物、甲型葡萄糖苷酶抑制劑、腸泌素調節劑等。此外,自古以來,中草藥廣泛應用於治療糖尿病。例如,於亞洲及非洲,青牛膽屬的寬筋藤已被廣泛運用於治療糖尿病患。本篇論文則探討分離自寬筋藤的borapetoside C與borapetoside A及由中草藥之萃取物GYT-067之降血糖功效。
首先,borapetoside C是一種具有clerodane結構的類萜類衍生物,分離自寬筋藤中的一個二萜類降血糖化合物。於小鼠實驗中發現borapetoside C在腹腔注射投與0.5 mg/kg六十分鐘後即能有效改善血糖值。而此降血糖作用於正常與第二型糖尿病小鼠模式中,可能和藥物投與後增加血液中胰島素含量有關,然而在胰島素分泌缺乏的第一型糖尿病小鼠模式中,borapetoside C並不會提高血中胰島素含量。在正常及第二型糖尿病小鼠,borapetoside C不但可以降低腹腔注射葡萄糖耐受性試驗之血糖值,還可促進骨骼肌肝醣合成量。在七天治療後,borapetoside C還能降低第一型糖尿病小鼠因病態提升的肝臟中磷酸烯醇式丙酮酸羧激酶 (PEPCK) 之蛋白表現量。 其次,腹腔注射 5 mg/kg borapetoside C 單次投與正常與第二型糖尿病小鼠後,亦能降低口服葡萄糖耐受性試驗血糖值。若與正對照組──胰島素 (1 IU/kg, i.p.) 相比,borapetoside C更能增加第二型糖尿病小鼠骨骼肌肝醣合成量。七天連續治療後,borapetoside C能增加胰島素受體 (IR)、蛋白質激酶B (Akt) 磷酸化與第二亞型葡萄糖轉運蛋白的表現量。另一方面,低劑量 (0.1 mg/kg) borapetoside C 與胰島素併用之下,能增加胰島素誘發之降血糖能力與胰島素促使肌肉肝醣合成增加之現象。而在七天治療後發現,borapetoside C與胰島素併用組別,更能增加胰島素受體、蛋白質激酶磷酸化與第二亞型葡萄糖轉運蛋白表現量。因此,此部分實驗證明borapetoside C能增加葡萄糖利用率、延緩胰島素阻抗的進程並增加胰島素敏感性。當糖尿病小鼠體內之胰島素受體─蛋白質激酶B─葡萄糖轉運蛋白的訊息傳遞路徑增強,進一步增加胰島素敏感性可能是borapetoside C達到降血糖功效之機轉。 另外,從寬筋藤中得到的較微量成分borapetoside A在10-8至10-7 M濃度下即能有效增加培養細胞 (C2C12及Hep3B) 之肝醣合成。在動物體之降血糖作用評估,亦發現在正常與第二型糖尿病小鼠模式中,borapetoside A透過增加胰島素分泌而達到降血糖功效;然而,在第一型糖尿病小鼠模式中,borapetoside A不會增加體內胰島素含量,但在腹腔注射投與10 mg/kg之降血糖功效與正對照組 metformin 300 mg/kg 相當。另外,borapetoside A不但具有改善腹腔注射葡萄糖試驗之血糖值,亦可增加肌肉肝醣含量。此外,在每天兩次、共計七日療程後,borapetoside A可以改善肝臟胰島素訊息傳遞途徑與病態增加的磷酸烯醇式丙酮酸羧激酶之蛋白表現量。 另,從植物中萃取出的GYT-067能明顯降低實驗動物體重、攝食與飲水量。GYT-067亦能改善腹腔注射葡萄糖耐受性試驗中血糖提升之現象。另外,二十八天治療後,GYT-067能顯著降低肝臟磷酸烯醇式丙酮酸羧激酶 (PEPCK) 的蛋白表現量;在脂肪組織處,GYT-067組之脂肪細胞尺寸明顯小於負對照組。因此,我們進行一連串GYT-067分離流程中各萃取物質之藥理活性測試,以期找出有效部分。 基於上述各部分實驗,我們可以知道borapetoside C和borapetoside A不但具有胰島素依存性,亦具有非胰島素依存性的作用。此外,borapetoside C還具有延緩胰島素阻抗、增加胰島素敏感性之功效。另一方面,於第二型糖尿病小鼠模式中,GYT-067萃取物與metformin有相似之降血糖作用。雖然針對borapetoside C、borapetoside A與GYT-067 等藥物之詳細的降血糖機制尚未完全明瞭,但由目前研究結果顯示這些藥物具優秀潛力開發成為新降低血糖藥物。 | zh_TW |
dc.description.abstract | Diabetes mellitus (DM), one of the metabolic disorders ranked among the top ten causes of mortality, often leads to neurological and vascular complications, and in severe conditions could result in limb amputation. The number of DM patient is expected to double at 2030 comparing to that in 2000 due to population growth, increase in aging population, urbanization, unhealthy diet, and soaring incidences of obesities and sedentary lifestyles. Numerous prior studies have proven that diabetes is associated with abnormal insulin release and sensitivity which result in increased hepatic glucose production and reduced glucose uptake in muscles. Nowadays, several classes of oral antidiabetic agents are available. However, the use of herbal remedies as DM treatments has been practiced since ancient times. For example, Tinospora crispa has been widely used in Asia and Africa as a remedy for diabetes and other diseases. In this study, the hypoglycemic effects of borapetoside C and borapetoside A, the pure active principles from Tinospora crispa, and GYT-067, a crude extract from a herbal plant, are explored.
Borapetoside C is a clerodane type terpene derivative isolated from Tinospora crispa. When injected intraperitoneally at doses ranging from 0.5 to 5 mg/kg in mice, borapetoside C decreased plasma glucose concentration within one hour. Such hypoglycemic effect seemed to be associated with an increase in the plasma insulin in normal and type 2 DM (T2DM) mice, but not in type 1 DM (T1DM) mice, where the insulin level remained constant. Borapetoside C treatment not only attenuated the elevation of plasma glucose level induced by an intraperitoneal glucose tolerance test (IPGTT), but also stimulated glycogen synthesis. Moreover, the elevated protein level of phosphoenolpyruvate carboxykinase (PEPCK) in the liver of T1DM mice was reversed after borapetoside C treatment. Acute treatment with borapetoside C (5 mg/kg) attenuated the elevated plasma glucose induced by oral glucose challenge in normal and T2DM mice. Compared to the effect of insulin, borapetoside C caused a more prominent increase of glycogen content in skeletal muscle of T2DM mice. Continuous treatment with 5 mg/kg borapetoside C for 7 days increased phosphorylation of insulin receptor (IR) and protein kinase B (Akt) as well as the expression of glucose transporter-2 (GLUT2) in T1DM mice. Combined treatment of a low dose borapetoside C (0.1 mg/kg) with insulin enhanced insulin-induced lowering of the plasma glucose level and insulin-induced increase of muscle glycogen content. Such treatment for 7 days enhanced insulin-induced IR and Akt phosphorylation and GLUT2 expression in the liver of T1DM mice. Thirdly, borapetoside A, a minor diterpenoid glycoside from T. crispa, was shown to increase the glycogen content and decrease the plasma glucose concentration in a dose-dependent manner both in vitro and in vivo. The hypoglycemic effects of borapetoside A in the normal healthy mice and T2DM mice were associated with the increases of the plasma insulin levels; whereas, the insulin levels remained unchanged in T1DM mice. Borapetoside A not only attenuated the elevation of plasma glucose induced by an IPGTT, but also increased the glycogen synthesis. Moreover, the elevated protein expression level of PEPCK, which is caused by the dysfunction of insulin signal pathway in the liver of T1DM mice, was reversed after borapetoside A treatment. Treatment with GYT-067, a polysaccharide containing extract from a medical herb, produced a significant reduction in body weight, food and water intake. GYT-067 attenuated the elevation of plasma glucose induced by an IPGTT and increased glycogen synthesis. Also, GYT-067 significantly reversed the elevated hepatic protein levels of PEPCK after treatment with GYT-067 daily for 28 days. Moreover, after 4-week treatment of GYT-067, the adipocyte size was smaller than vehicle-treatment group. Therefore, we checked the hypoglycemic activity of sequential purification GYT-067 in the process to find the active components. Based on the studies of hypoglycemic activity of chemical principles from T. crispa, we conclude that the mechanisms involved in the hypoglycemic effect of borapetodie C and borapetoside A include insulin-dependent and -independent pathways. Moreover, borapetoside C delayed the development of insulin resistance in association with increased insulin sensitivity. On the other hand, GYT-067, a crude extract from other plant, exerts similar mode of hypoglycemic actin as metformin in T2DM mice. Although the underlying mechanisms for the hypoglycemic activities of borapetoside C, borapetoside A, and GYT-067 remain to be determined, their well-characterized antidiabetic activities suggest that they highly potential be used as alternative agent for the treatment of diabetes in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T00:19:58Z (GMT). No. of bitstreams: 1 ntu-101-F95443014-1.pdf: 5178539 bytes, checksum: f63eabea1f44f7a62ebda9e25d5ed444 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 口試委員會審定書 i
致謝 iii 中文摘要 v Abstract ix 縮寫指引 (Abbreviations) xiii 目錄 (Contents) xv 圖目錄 (Figure contents) xx 表目錄 (Table contents) xxiii 第1章 緒論 (Introduction) 1 1.1 前言 1 1.2 文獻探討 2 1.2.1 葡萄糖在體內的恆定 2 1.2.2 糖尿病的分類與流行病學 3 1.2.3 胰島素產生降血糖作用之機轉 6 1.2.4 糖尿病藥物介紹 7 1.2.5 中草藥於治療糖尿病之研究 12 1.3 研究目的 14 第2章 實驗材料與方法 (Materials and Methods) 15 2.1 實驗動物與細胞 15 2.1.1 實驗動物 15 2.1.2 實驗用細胞株 15 2.2 實驗材料 16 2.2.1 Borapetoside A或borapetoside C來源 16 2.2.2 GYT-067 來源 17 2.3 實驗方法 17 2.3.1 糖尿病動物模式誘發 17 2.3.2 劑量依賴性降血糖作用之評估 17 2.3.3 測血糖與胰島素之方法 18 2.3.4 腹腔注射葡萄糖耐受性試驗 19 2.3.5 口服葡萄糖耐受性試驗 19 2.3.6 口服蔗糖耐受性試驗 19 2.3.7 胰島素耐受性試驗 20 2.3.8 動物骨骼肌與肝臟之肝醣合成分析方法 20 2.3.9 連續投與borapetoside對小鼠肝臟蛋白表現之影響 20 2.3.10 蛋白質萃取與濃度測定 21 2.3.11 西方墨點分析法 22 2.3.12 C2C12與Hep3B中劑量依賴性肝醣合成分析法 23 2.3.13 攝食量與飲水量之量取 24 2.3.14 連續投與GYT-067於第二型糖尿病小鼠之實驗方法 24 2.3.15 蘇木紫-伊紅染色法 (Hematoxylin and eosin stain) 25 2.3.16 統計方法 25 第3章 Borapetoside C在正常與糖尿病小鼠模式中降血糖作用 (Hypoglycemic effects of borapetoside C in normal and diabetic mice.) 28 3.1 Borapetoside C劑量相關性的降血糖作用 28 3.2 Borapetoside C 刺激胰島素釋放之作用 28 3.3 Borapetoside C能顯著增加葡萄糖利用率 29 3.4 Borapetoside C連續治療後能改善病態提升的PEPCK蛋白表現量 30 3.5 討論 31 第4章 Borapetoside C具有改善糖尿病小鼠胰島素敏感性之功效 (Borapetoside C from Tinospora crispa Improves Insulin Sensitivity in Diabetic Mice) 40 4.1 Borapetoside C能改善口服葡萄糖耐受性 40 4.2 Borapetoside C 能刺激小鼠骨骼肌之肝醣合成 40 4.3 七天治療後,Borapetoside C 能活化第一型糖尿病小鼠肝臟的胰島素訊息傳遞路徑 41 4.4 低劑量borapetoside C能改善胰島素敏感性 41 4.5 低劑量borapetoside C配合短效胰島素能增加骨骼肌的肝醣合成 42 4.6 低劑量borapetoside C配合短效胰島素七天治療後,在第一型糖尿病小鼠肝臟之蛋白質表現量的影響 42 4.7 討論 44 第5章 於正常與糖尿病小鼠模式中,borapetoside A的抗糖尿病作用(Antidiabetic Action of Borapetoside A in Normal and Diabetic Mice.) 56 5.1 Borapetoside A能增加離體細胞C2C12與Hep3B之肝醣合成量 56 5.2 Borapetoside A對血糖與胰島素分泌量之影響 56 5.3 Borapetoside A對葡萄糖耐受性之影響 57 5.4 Borapetoside A 對於骨骼肌與肝臟的肝醣合成之影響 57 5.5 連續七天borapetoside A治療對於肝臟之訊息傳遞的影響 58 5.6 討論 59 第6章 GYT-067在第二型糖尿病小鼠中降血糖作用探討 (Antihyperglycemic action of GYT-067 in T2DM mice.) 72 6.1 口服GYT-067-1對飲食飲水量及體重之影響 72 6.2 GYT-067-1 對葡萄糖利用率的影響 72 6.3 GYT-067-1 對骨骼肌肝醣合成之影響 73 6.4 GYT-067-1 對小鼠脂肪與肝臟之影響 73 6.5 GYT-067-2 對飲食飲水量及體重之影響 73 6.6 GYT-067-H2O-insol 對葡萄糖利用率與骨骼肌肝醣合成的影響 73 6.7 GYT-067-3 與 GYT-067-4 對攝食飲水量、體重、葡萄糖利用及肝醣合成之影響 74 6.8 GYT-067-5 對攝食飲水量、體重、葡萄糖利用及肝醣合成之影響 74 6.9 GYT-067-6對飲食飲水量及體重之影響 75 6.10 GYT-067-6腹腔注射葡萄糖耐受性試驗及對骨骼肌肝醣合成之影響 75 6.11 GYT-067-6對口服葡萄糖耐受性之影響 76 6.12 GYT-067-6於口服蔗糖耐受性試驗之影響 76 6.13 討論 77 第7章 總結與未來展望 (Conclusion and future work) 109 第8章 參考文獻 (Reference) 111 已發表之著作 123 學術研討會論文 125 | |
dc.language.iso | zh-TW | |
dc.title | 中草藥二萜類與多醣體類化合物對小鼠降血糖作用之研究 | zh_TW |
dc.title | Hypoglycemic action of diterpenoids and polysaccharides from
herbal medicine in mice. | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 李水盛(Shoei-Sheng Lee),楊偉勛(Wei-Shiung Yang),顏茂雄(Mao-Hsiung Yen),林正一(Cheng-I Lin) | |
dc.subject.keyword | Tinospora crispa,borapetoside C,borapetoside A,降血糖作用,糖尿病小鼠, | zh_TW |
dc.subject.keyword | Tinospora crispa,borapetoside C,borapetoside A,hypoglycemia effect,diabetic mice, | en |
dc.relation.page | 126 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-06-25 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 5.06 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。